Drugs Containing Excipient (Inactive Ingredient) HYDROGENATED SOYBEAN OIL

Branded drugs containing HYDROGENATED SOYBEAN OIL excipient, and estimated key patent expiration / generic entry dates

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Novartis Pharmaceuticals Corporation	LAMPRENE	clofazimine	0078-1049	HYDROGENATED SOYBEAN OIL
Advanz Pharma (US) Corp	ZONEGRAN	zonisamide	59212-681	HYDROGENATED SOYBEAN OIL
H2-Pharma LLC	VESANOID	tretinoin	61269-750	HYDROGENATED SOYBEAN OIL

Generic drugs containing HYDROGENATED SOYBEAN OIL excipient

Company	Ingredient	NDC	Excipient
Novartis Pharmaceuticals Corporation	clofazimine	0078-1049	HYDROGENATED SOYBEAN OIL
Upsher-Smith Laboratories LLC	isotretinoin	0245-0570	HYDROGENATED SOYBEAN OIL
Upsher-Smith Laboratories LLC	isotretinoin	0245-0575	HYDROGENATED SOYBEAN OIL

Hydrogenated Soybean Oil Pharmaceutical Excipient Market Dynamics and Financial Trajectory

Last updated: September 1, 2026

Hydrogenated soybean oil is a specialty lipid excipient used mainly in oral solid dosage forms, modified-release systems, soft and hard capsules, and some topical or semisolid formulations. Its commercial outlook is tied to excipient-grade production capacity, soybean and hydrogenation costs, pharmaceutical outsourcing, and demand for lipid-based drug delivery. The market is fragmented, and manufacturers generally do not disclose revenue for hydrogenated soybean oil as a standalone product.

The product has limited direct patent exposure. Competitive barriers are more likely to arise from pharmaceutical-grade quality systems, impurity control, physical-property consistency, formulation know-how, regulatory documentation, and customer qualification requirements than from composition-of-matter patents.

What is hydrogenated soybean oil used for in pharmaceuticals?

Hydrogenated soybean oil is a hardened, partially or fully hydrogenated soybean-derived lipid. Hydrogenation increases melting point, oxidative stability, hardness, and resistance to rancidity compared with liquid soybean oil.

Pharmaceutical uses include:

• Tablet and capsule lubricant
• Binder or carrier in lipid-based formulations
• Matrix former for sustained-release tablets
• Hydrophobic coating or release-modifying excipient
• Vehicle for active pharmaceutical ingredients with poor water solubility
• Component of semisolid and topical formulations
• Processing aid in direct compression or granulation
• Carrier in multiparticulate and pellet systems

Its performance depends on fatty-acid composition, degree of hydrogenation, iodine value, melting range, particle size, surface area, polymorphism, and residual catalyst or process impurities.

Hydrogenated soybean oil is not interchangeable with every hydrogenated vegetable oil. Suppliers may use different source oils, hydrogenation levels, purification methods, and nomenclature. A formulation qualified against a specific grade may require a new development program if the supplier changes the material or manufacturing site.

How does hydrogenated soybean oil compare with competing pharmaceutical excipients?

Hydrogenated soybean oil competes with other hydrophobic lipids and solid excipients. Selection depends on release profile, compression behavior, melting point, compatibility, regulatory status, and cost.

Excipient	Primary pharmaceutical role	Relative commercial position	Main limitation
Hydrogenated soybean oil	Lubricant, carrier, matrix former	Cost-sensitive specialty excipient	Batch variability and source-material scrutiny
Hydrogenated vegetable oil	Lubricant and tablet-processing aid	Broad, established category	Source may be unclear unless fully specified
Glyceryl behenate	Lipid matrix and lubricant	Stronger position in controlled release	Higher cost in some applications
Glyceryl palmitostearate	Lubricant and release modifier	Established lipid excipient	Performance varies by grade
Stearic acid	Lubricant and hydrophobic release modifier	Commodity-like and widely available	Can affect dissolution and tablet strength
Magnesium stearate	Lubricant	Dominant tablet lubricant	Over-lubrication can reduce dissolution or tablet hardness
Waxes	Matrix former and coating component	Niche and formulation-specific	Processing and dissolution constraints
Poloxamers and PEG lipids	Solubilizer and delivery-system component	Higher-value specialty segment	Greater formulation cost and complexity

Hydrogenated soybean oil is most competitive where the formulator needs a solid lipid with a moderate cost profile and does not require the highly defined performance associated with more specialized lipid excipients.

Glyceryl behenate and glyceryl palmitostearate generally have stronger positioning in controlled-release applications because their chemical composition and pharmaceutical use are well established. Hydrogenated soybean oil can compete when the formulation is less sensitive to exact lipid composition or when procurement cost is a primary consideration.

What are the main market dynamics for hydrogenated soybean oil?

Pharmaceutical outsourcing is the strongest structural demand driver

Contract development and manufacturing organizations increasingly manage formulation development, scale-up, and commercial manufacturing for generic drugs, branded medicines, and consumer-health products. This supports demand for excipients that are available in repeatable pharmaceutical grades and supported by regulatory documentation.

Hydrogenated soybean oil benefits when it is incorporated into platform formulations used across multiple products. It is less attractive when a drug developer needs a narrow dissolution profile, high chemical definition, or extensive regulatory precedent.

Modified-release dosage forms support higher-value applications

Immediate-release tablets usually place greater emphasis on low cost and manufacturing performance. Modified-release tablets, pellets, lipid matrices, and poorly soluble drug formulations require more formulation development and can support higher excipient value per kilogram.

In these applications, the supplier's value is determined by technical support and batch consistency rather than by raw-material price alone. A qualified grade may remain in a formulation for years because changing the excipient can trigger comparative dissolution, stability, and process-validation work.

Soybean sourcing creates agricultural cost exposure

The underlying raw material is linked to soybean prices, energy costs, hydrogen costs, transport, and edible-oil processing economics. Pharmaceutical-grade material also carries costs for purification, testing, documentation, packaging, and quality assurance.

Input-cost transmission is not automatic. Large pharmaceutical customers often negotiate annual pricing, while excipient suppliers may carry some volatility in margins when agricultural costs rise rapidly. Producers with integrated hydrogenation or oil-processing capabilities have greater control over supply and conversion costs.

Regulatory scrutiny favors traceability

Soy-derived materials can raise questions about allergens, genetically modified organisms, residual solvents, catalyst residues, pesticides, heavy metals, and animal-origin contamination. Hydrogenated soybean oil does not have the same animal-origin risk profile as tallow-derived materials, but customers may still require extensive origin and process documentation.

The European Medicines Agency requires excipient information to address quality, safety, and functional suitability in pharmaceutical products. The United States Pharmacopeia-National Formulary provides applicable monographs and general quality standards where a material is covered. FDA inactive-ingredient databases provide precedent for excipient use by dosage form and route, although database inclusion does not constitute blanket approval of every grade or supplier. [1-3]

What is the financial trajectory for hydrogenated soybean oil?

No major public supplier reports hydrogenated soybean oil as a separate revenue line. Financial analysis therefore depends on market structure, application mix, pricing, and supplier exposure rather than a standalone audited market series.

The likely financial trajectory is a low-to-moderate volume-growth business with selective margin expansion in pharmaceutical-grade and formulation-supported applications.

Financial driver	Near-term effect	Medium-term effect
Soybean and energy costs	Margin volatility	Greater pressure for indexed pricing
Generic-drug production	Supports volume	Stable recurring demand
Modified-release formulations	Supports value per kilogram	Improves product mix
Supplier qualification	Raises switching costs	Supports customer retention
Regulatory documentation	Raises operating cost	Favors established suppliers
Competition from other lipids	Limits pricing power	Encourages differentiated grades
Sustainable sourcing requirements	Raises compliance cost	May support premium products
Capacity expansion	Can pressure prices	Improves supply reliability

The highest-margin segment is likely pharmaceutical-grade material supplied with regulatory support, analytical specifications, technical service, and controlled manufacturing. Bulk material sold primarily on price faces competition from other hydrogenated oils and commodity lipid excipients.

Revenue exposure is concentrated at the customer level

A single excipient may represent a small share of a drug's bill of materials while remaining commercially important to the supplier. Customers typically purchase relatively modest quantities compared with commodity food or industrial applications, but pharmaceutical orders can produce recurring demand and long qualification periods.

Revenue concentration can be high if a supplier depends on a small number of major generic-drug manufacturers, capsule producers, or contract manufacturers. Product discontinuations, reformulation, supplier changes, and loss of an approved manufacturing site can materially affect demand.

Which companies compete in hydrogenated soybean oil excipients?

The market includes specialty excipient manufacturers, lipid-technology companies, pharmaceutical raw-material distributors, and broader vegetable-oil processors. Public company disclosures often group these products into larger categories such as excipients, specialty ingredients, pharmaceutical solutions, or health-care products.

Competitive differentiation typically rests on:

1. Pharmaceutical-grade manufacturing and batch release
2. Global regulatory support
3. Consistent melting and flow properties
4. Low peroxide and controlled oxidation levels
5. Allergen and GMO documentation
6. Multi-site supply or validated business continuity
7. Technical support for compression, coating, and dissolution
8. Packaging that protects against moisture, heat, and oxidation

The main competitive threat is substitution rather than direct entry by a single named competitor. Formulators can replace hydrogenated soybean oil with glyceryl behenate, glyceryl palmitostearate, stearic acid, hydrogenated cottonseed oil, waxes, or other solid lipids if the substitute satisfies performance and regulatory requirements.

What patents protect hydrogenated soybean oil?

Hydrogenated soybean oil generally does not have a meaningful standalone composition-of-matter patent estate. The material is a processed mixture of hydrogenated triglycerides rather than a single novel molecular entity.

Patent protection may instead cover:

• A drug formulation containing hydrogenated soybean oil
• A sustained-release matrix using the excipient
• A lipid nanoparticle or self-emulsifying delivery system
• A specific particle-size distribution
• A hydrogenation or purification process
• A combination of hydrogenated soybean oil with other excipients
• A dosage form with a defined dissolution profile

These patents usually protect the pharmaceutical formulation or manufacturing method, not the excipient itself.

How strong is the patent estate for hydrogenated soybean oil?

The excipient-level patent estate is generally weak to moderate. Trade secrets, manufacturing controls, supplier qualification, and customer-specific formulation data are more important barriers.

A supplier may have protectable know-how around:

• Hydrogenation conditions
• Catalyst removal
• Deodorization and purification
• Control of trans-fatty-acid content
• Oxidative-stability improvement
• Particle engineering
• Blending and granulation
• Packaging and storage conditions

Patent strength increases when a grade delivers a demonstrated pharmaceutical function that competitors cannot reproduce without materially changing dissolution, stability, or manufacturability.

What is the FDA regulatory status and Orange Book position?

Hydrogenated soybean oil is an excipient, not an approved active pharmaceutical ingredient. It does not have an independent FDA approval pathway comparable to a drug substance.

The regulatory position is product-specific:

• The finished drug application identifies the excipient and its amount.
• The applicant must demonstrate suitability for the intended dosage form and route.
• FDA reviewers assess quality, safety, manufacturing controls, and formulation performance within the drug application.
• The inactive-ingredient database can provide precedent but does not eliminate the need for product-specific justification.
• Excipient changes may require regulatory reporting, comparative dissolution, stability data, or prior approval depending on the application and change category. [1,2]

Hydrogenated soybean oil is not listed in the Orange Book as a standalone pharmaceutical product. It has no independent Orange Book exclusivity, no standalone Paragraph IV challenge, and no separate Hatch-Waxman patent listing.

When does hydrogenated soybean oil lose exclusivity?

Hydrogenated soybean oil does not normally have drug-like market exclusivity. There is no standard exclusivity expiration date for the excipient itself.

Exclusivity may exist indirectly through:

• A formulation patent
• A drug product patent listed by FDA
• A proprietary modified-release platform
• A supplier-specific qualification
• A confidential manufacturing process
• A customer agreement
• A regulatory file that is difficult to replicate

A generic competitor can usually use the same type of excipient if it independently meets quality and formulation requirements. The commercial barrier is often qualification and performance replication rather than legal exclusivity.

What manufacturing and intellectual-property barriers affect supply?

The key manufacturing barriers are process control and pharmaceutical quality assurance.

Critical attributes include:

• Fatty-acid profile
• Melting range
• Solid-fat content
• Acid value
• Peroxide value
• Iodine value
• Moisture
• Residual catalyst
• Microbial quality
• Particle-size distribution
• Bulk density
• Oxidative stability

Hydrogenation can create variation in cis-trans composition and physical behavior. That variation can affect tablet lubrication, compactability, dissolution, and stability. A supplier that provides narrow specifications and reliable lot-to-lot performance can retain customers even when alternative materials are cheaper.

Geographic coverage also matters. Pharmaceutical customers favor suppliers with qualified manufacturing sites, regional warehouses, controlled logistics, and documented business-continuity plans. Production concentrated in one region creates exposure to crop failures, energy disruptions, shipping constraints, and regulatory inspections.

What generic entry risks exist for drugs using hydrogenated soybean oil?

The excipient itself is rarely the principal generic-entry risk. The larger risks are:

• A formulation patent covering the drug-excipient combination
• A method-of-use patent tied to a release profile
• A drug-device or multiparticulate patent
• A manufacturing patent covering lipid dispersion or coating
• Difficulty reproducing dissolution or bioequivalence
• Supplier changes that alter product performance
• Regulatory questions about soy origin or impurities

For immediate-release products, substitution risk is high because multiple lubricants and hydrophobic excipients may be available. For controlled-release or poorly soluble drugs, substitution risk is lower because the excipient may be embedded in a validated formulation architecture.

What licensing deals and settlement agreements affect the market?

Hydrogenated soybean oil suppliers typically compete through supply agreements, quality agreements, technical-development arrangements, and preferred-vendor programs rather than public intellectual-property licenses.

Publicly disclosed patent settlements are generally associated with the finished drug formulation, not with hydrogenated soybean oil as an excipient. A settlement involving a drug product may restrict use of a formulation or delay generic entry, but it does not create exclusivity for the excipient itself.

Key Takeaways

• Hydrogenated soybean oil is a specialty lipid excipient used in tablets, capsules, modified-release systems, and lipid-based formulations.
• Its standalone market size and revenue are not separately disclosed by major suppliers.
• Volume growth is linked to generic drugs, contract manufacturing, modified-release products, and poorly soluble compounds.
• Financial performance is exposed to soybean, hydrogen, energy, packaging, and logistics costs.
• Pharmaceutical-grade products can earn better margins than bulk hydrogenated oils because of documentation, qualification, and technical-service requirements.
• The excipient has limited standalone patent protection.
• Formulation patents, manufacturing know-how, supplier qualification, and regulatory documentation are the main commercial barriers.
• FDA and Orange Book exclusivity apply to finished drug products, not to hydrogenated soybean oil itself.
• The principal competitive threat is substitution by glyceryl behenate, glyceryl palmitostearate, stearic acid, hydrogenated vegetable oils, and wax-based excipients.
• The most defensible suppliers are those with consistent physical specifications, global regulatory support, validated production, and formulation-development capabilities.

FAQs

Is hydrogenated soybean oil the same as hydrogenated vegetable oil?

No. Hydrogenated vegetable oil is a broader designation that may include soybean, cottonseed, palm, rapeseed, or blended sources. Pharmaceutical qualification should identify the actual source and material specifications.

Is hydrogenated soybean oil safe in oral drug products?

Its use is assessed within the finished drug application. Safety depends on the grade, amount, route, impurities, manufacturing controls, and available regulatory precedent.

Can hydrogenated soybean oil be used in vegetarian or vegan medicines?

It is generally plant-derived, but the final determination depends on the supplier's sourcing, processing aids, capsule shell, and full formulation. Pharmaceutical customers require documented origin information.

Does hydrogenated soybean oil create a soy-allergen issue?

Hydrogenation and refining can reduce protein residues, but allergen status depends on manufacturing and purification controls. Suppliers should provide product-specific allergen documentation.

Is hydrogenated soybean oil suitable for controlled-release tablets?

Yes. Its hydrophobic character and melting behavior can support matrix systems and release modification, but performance must be established through formulation and dissolution testing.

References

1. U.S. Food and Drug Administration. (n.d.). Inactive ingredient database. https://www.accessdata.fda.gov/scripts/cder/iig/index.cfm

2. U.S. Food and Drug Administration. (2019). ANDAs for certain highly purified synthetic and semi-synthetic ingredients. FDA guidance and abbreviated new drug application framework.

3. United States Pharmacopeial Convention. (2024). United States Pharmacopeia and National Formulary. USP.

4. European Medicines Agency. (2016). Guideline on excipients in the dossier for application for marketing authorisation of a medicinal product. EMA/CHMP/QWP/396951/2006.

5. European Directorate for the Quality of Medicines & HealthCare. (2023). European Pharmacopoeia. Council of Europe.